610 related articles for article (PubMed ID: 19139988)
1. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
[TBL] [Abstract][Full Text] [Related]
2. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
4. Does hormonal therapy decrease tamoxifen associated hot flashes?
Barton DL; Loprinzi CL
Breast Cancer Res Treat; 2009 Aug; 116(3):529-30. PubMed ID: 19205876
[No Abstract] [Full Text] [Related]
5. Type of menopause, patterns of hormone therapy use, and hot flashes.
Gallicchio L; Whiteman MK; Tomic D; Miller KP; Langenberg P; Flaws JA
Fertil Steril; 2006 May; 85(5):1432-40. PubMed ID: 16566933
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
Goodwin JW; Green SJ; Moinpour CM; Bearden JD; Giguere JK; Jiang CS; Lippman SM; Martino S; Albain KS
J Clin Oncol; 2008 Apr; 26(10):1650-6. PubMed ID: 18375894
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms.
Lindh-Astrand L; Bixo M; Hirschberg AL; Sundström-Poromaa I; Hammar M
Menopause; 2010; 17(1):72-9. PubMed ID: 19675505
[TBL] [Abstract][Full Text] [Related]
8. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial.
Walker EM; Rodriguez AI; Kohn B; Ball RM; Pegg J; Pocock JR; Nunez R; Peterson E; Jakary S; Levine RA
J Clin Oncol; 2010 Feb; 28(4):634-40. PubMed ID: 20038728
[TBL] [Abstract][Full Text] [Related]
9. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
Wang PH; Horng HC; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):127-34. PubMed ID: 17638620
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
[TBL] [Abstract][Full Text] [Related]
11. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
Col NF; Chlebowski RT
Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
[TBL] [Abstract][Full Text] [Related]
13. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy (HT) in patients with breast cancer.
Batur P; Blixen CE; Moore HC; Thacker HL; Xu M
Maturitas; 2006 Jan; 53(2):123-32. PubMed ID: 16368466
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hot flashes in women with a previous diagnosis of breast cancer].
Debourdeau P; Bachelot T; Zammit C; Aletti M; Gallineau C; Gligorov J
Bull Cancer; 2004 Apr; 91(4):339-49. PubMed ID: 15242316
[TBL] [Abstract][Full Text] [Related]
17. Vasomotor symptoms decrease in women with breast cancer randomized to treatment with applied relaxation or electro-acupuncture: a preliminary study.
Nedstrand E; Wijma K; Wyon Y; Hammar M
Climacteric; 2005 Sep; 8(3):243-50. PubMed ID: 16390756
[TBL] [Abstract][Full Text] [Related]
18. The management of menopausal symptoms in women with breast cancer.
Jubelirer SJ
W V Med J; 1995 Feb; 91(2):54-6. PubMed ID: 7610643
[TBL] [Abstract][Full Text] [Related]
19. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Stovall DW; Pinkerton JV
Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial.
Frisk J; Carlhäll S; Källström AC; Lindh-Astrand L; Malmström A; Hammar M
Climacteric; 2008 Apr; 11(2):166-74. PubMed ID: 18365859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
